1. Home
  2. OCGN vs IMRX Comparison

OCGN vs IMRX Comparison

Compare OCGN & IMRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Ocugen Inc.

OCGN

Ocugen Inc.

HOLD

Current Price

$1.78

Market Cap

387.3M

Sector

Health Care

ML Signal

HOLD

Logo Immuneering Corporation

IMRX

Immuneering Corporation

HOLD

Current Price

$5.24

Market Cap

340.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
OCGN
IMRX
Founded
2013
2008
Country
United States
United States
Employees
N/A
53
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
387.3M
340.7M
IPO Year
2014
2021

Fundamental Metrics

Financial Performance
Metric
OCGN
IMRX
Price
$1.78
$5.24
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
4
5
Target Price
$9.75
$17.20
AVG Volume (30 Days)
10.7M
802.2K
Earning Date
03-04-2026
03-06-2026
Dividend Yield
N/A
N/A
EPS Growth
31.58
37.75
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$2,980.89
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.57
$1.10
52 Week High
$2.73
$10.08

Technical Indicators

Market Signals
Indicator
OCGN
IMRX
Relative Strength Index (RSI) 45.77 53.43
Support Level $1.47 $4.83
Resistance Level $2.73 $5.36
Average True Range (ATR) 0.23 0.29
MACD -0.07 0.00
Stochastic Oscillator 8.04 57.77

Price Performance

Historical Comparison
OCGN
IMRX

About OCGN Ocugen Inc.

Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").

About IMRX Immuneering Corporation

Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.

Share on Social Networks: